| 2022-09-14 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2022-08-04 |
详情>>
股本变动：
变动后总股本6058.32万股
变动原因 ▼▲
- 原因：
- From March 31, 2022 to June 30, 2022
Net proceeds from issuance of common stock
Share-based compensation
|
| 2022-08-04 |
详情>>
业绩披露：
2022年中报每股收益-0.18美元,归母净利润-1085.2万美元,同比去年增长21.05%
|
| 2022-08-04 |
财报披露：
美东时间 2022-08-04 盘后发布财报
|
| 2022-05-24 |
复牌提示：
2022-05-23 16:03:00 停牌，复牌日期 2022-05-23 16:35:00
|
| 2022-05-05 |
详情>>
业绩披露：
2022年一季报每股收益-0.07美元,归母净利润-422.6万美元,同比去年增长47.59%
|
| 2022-03-22 |
详情>>
业绩披露：
2021年年报每股收益-0.5美元,归母净利润-2746.6万美元,同比去年增长-237.01%
|
| 2021-11-04 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.38美元,归母净利润-2067.2万美元,同比去年增长-660.28%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-05 |
详情>>
业绩披露：
2021年中报每股收益-0.27美元,归母净利润-1374.5万美元,同比去年增长-627.03%
|
| 2021-05-06 |
详情>>
业绩披露：
2021年一季报每股收益-0.19美元,归母净利润-806.3万美元,同比去年增长-102.08%
|
| 2021-04-28 |
股东大会：
将于2021-06-16召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Gregory B. Brown, M.D. and David J. Mazzo, Ph.D. as Class II directors to serve a three-year term expiring at the annual meeting to be held in 2024;
2.To ratify the appointment of Grant Thornton LLP as Caladrius' independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To approve, on a non-binding advisory basis, the executive compensation of Caladrius' named executive officers as disclosed in this Proxy Statement;
4.To approve an amendment to the Caladrius Biosciences, Inc. 2018 Equity Incentive Compensation Plan (the "Plan") that increases the number of shares of common stock that may be issued under the Plan by 6,000,000;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-02-25 |
详情>>
业绩披露：
2020年年报每股收益-0.53美元,归母净利润-815万美元,同比去年增长57.91%
|
| 2020-11-05 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-0.19美元,归母净利润-271.9万美元,同比去年增长81.12%
|
| 2020-08-13 |
详情>>
业绩披露：
2020年中报每股收益0.22美元,归母净利润260.80万美元,同比去年增长127.43%
|
| 2020-05-07 |
详情>>
业绩披露：
2020年一季报每股收益-0.38美元,归母净利润-399万美元,同比去年增长8.63%
|
| 2020-04-29 |
股东大会：
将于2020-06-18召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Cynthia S. Schwalm and Peter G. Traber, M.D. as Class I directors to serve a three-year term expiring at the annual meeting to be held in 2023;
2.To ratify the appointment of Grant Thornton LLP as Caladrius' independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To approve, on a non-binding advisory basis, the executive compensation of Caladrius' named executive officers as disclosed in this Proxy Statement;
4.To approve an amendment to the Caladrius Biosciences, Inc. 2018 Equity Incentive Compensation Plan (the "Plan") that increases the number of shares of common stock that may be issued under the Plan by 1,000,000;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-04-30 |
股东大会：
将于2019-06-27召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Steven M. Klosk and Steven S. Myers as Class III directors to serve a three-year term expiring at the annual meeting to be held in 2022;
2.To ratify the appointment of Grant Thornton LLP as Caladrius' independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To approve, on a non-binding advisory basis, the executive compensation of Caladrius' named executive officers as disclosed in this Proxy Statement;
4.To approve, on a non-binding advisory basis, the frequency of holding stockholder advisory votes on the executive compensation of Caladrius' named executive officers;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-01-08 |
详情>>
内部人交易：
BROWN GREGORY B等共交易7笔
|
| 2018-04-24 |
股东大会：
将于2018-06-20召开股东大会
会议内容 ▼▲
- 1.To re-elect each of Gregory B. Brown, M.D. and David J. Mazzo, Ph.D. as Class II directors to serve a three-year term expiring at the annual meeting to be held in 2021;
2.To approve the adoption of the Caladrius Biosciences, Inc. 2018 Equity Incentive Compensation Plan;
3.To approve an amendment to the 2017 Employee Stock Purchase Plan to increase the number of shares available to 500,000;
4.To ratify the appointment of Grant Thornton LLP as Caladrius' independent registered public accounting firm for the fiscal year ending December 31, 2018;
5.To approve, on a non-binding advisory basis, the executive compensation of Caladrius' named executive officers as disclosed in this Proxy Statement;
6.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2017-04-11 |
股东大会：
将于2017-05-16召开股东大会
会议内容 ▼▲
- 1.To approve the adoption of the interest purchase agreement (the “Purchase Agreement”), dated as of March 16, 2017, by and among Caladrius, PCT, LLC, a Caladrius Company (“PCT”), and Hitachi Chemical Co. America, Ltd. (“Hitachi”), pursuant to which Hitachi will acquire from Caladrius the 80.1% membership interest in PCT that it does not already own for $75.0 million in cash (the “Sale”), subject to potential adjustment, including based on PCT’s cash and outstanding indebtedness as of the closing of the Sale, a potential future milestone payment based on PCT’s revenue in 2017-2018 and certain transaction expenses;
2.To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to Caladrius’ named executive officers in connection with the Sale, including the agreements and understandings pursuant to which such compensation may be paid or become payable;
3.To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposal to adopt Purchase Agreement;
4.To elect one Class I director to serve until the annual meeting to be held in 2020;
5.To approve the adoption of Caladrius Biosciences, Inc.’s 2017 Employee Stock Purchase Plan;
6.To approve, on a non-binding, advisory basis, the executive compensation of Caladrius’ named executive officers as described in the accompanying proxy statement;
7.To ratify the appointment of Grant Thornton LLP as Caladrius’ independent registered public accounting firm for the fiscal year ending December 31, 2017;
8.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2016-07-27 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2016-05-10 |
股东大会：
将于2016-06-22召开股东大会
会议内容 ▼▲
- 1.To elect four Class III directors to serve until the annual meeting to be held in 2019;
2.To approve, on a non-binding advisory basis, the executive compensation of Caladrius’ named executive officers as described in this Proxy Statement;
3.To approve an amendment to Caladrius' certificate of incorporation to effect a reverse stock split of Caladrius common stock (in the event it is deemed by the Caladrius Board of Directors to be advisable) at a ratio within the range of 1:2 to 1:10, as determined by the Caladrius Board of Directors;
4.To ratify the appointment of Grant Thornton LLP as Caladrius' independent registered public accounting firm for the fiscal year ending December 31, 2016;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2015-06-08 |
股东大会：
将于2015-07-14召开股东大会
会议内容 ▼▲
- 1.To elect one Class II director to serve until the annual meeting to be held in 2018;
2.To approve, on a non-binding advisory basis, the executive compensation of Caladrius’ named executive officers as described in this Proxy Statement;
3.To approve Caladrius’ 2015 Equity Compensation Plan;
4.To ratify the appointment of Grant Thornton LLP as Caladrius’ independent registered public accounting firm for the fiscal year ending December 31, 2015;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2014-08-29 |
股东大会：
将于2014-10-06召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors to serve until the annual meeting to be held in 2017, and to elect one newly-appointed Class III director to serve until the annual meeting to be held in 2016;
2.To approve the issuance of shares of common stock in connection with milestone payments that may become payable in the future to former securityholders of California Stem Cell, Inc., in accordance with the Marketplace Rules of the NASDAQ Stock Market;
3.To approve, on a non-binding advisory basis, the executive compensation of NeoStem's named executive officers as described in this Proxy Statement;
4.To approve an amendment to NeoStem's Amended & Restated 2009 Equity Compensation Plan to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000 shares;
5.To ratify the appointment of Grant Thornton LLP as NeoStem's independent registered public accounting firm for the fiscal year ending December 31, 2014;
6.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2013-08-30 |
股东大会：
将于2013-10-03召开股东大会
会议内容 ▼▲
- 1. To adopt an Amended and Restated Certificate of Incorporation of NeoStem, including amendments to (a) provide for the classification of the Board of Directors into three classes, and certain related provisions regarding the Board of Directors, and (b) simplify the description of the business permitted to be carried on by NeoStem;
2. To elect seven directors;
3. To approve, on a non-binding advisory basis, the executive compensation of NeoStem's named executive officers as described in this Proxy Statement;
4. To vote, on a non-binding advisory basis, on the frequency of stockholder advisory votes on executive compensation;
5. To approve an amendment to NeoStem's Amended & Restated 2009 Equity Compensation Plan to increase the number of shares of common stock authorized for issuance thereunder by 2,600,000 shares;
6. To ratify the appointment of Grant Thornton LLP as NeoStem's independent registered public accounting firm for the fiscal year ending December 31, 2013;
7. To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|